

Q3 2021 RESULTS



“ The third quarter of 2021 marked an excellent performance for Sanofi, with double digit sales growth and remarkable progress in R&D. ”

PAUL HUDSON
CHIEF EXECUTIVE OFFICER, SANOFI

COMPANY SALES & BUSINESS EPS*

Q3 2021 COMPANY SALES*

€10,432 M
+10.1% (+10.1%)

Q3 2021 BUSINESS EPS*

€2.18
+19.1% (+19.1%)

*Growth rates are expressed at constant exchange rates (CER).
Growth rates in parentheses are expressed on a reported basis.

€3,287 M
Specialty Care

€2,422 M
Vaccines

SALES BY GLOBAL BUSINESS UNIT

€3,568 M
General Medicines

€1,155 M
Consumer Healthcare

SALES BY GEOGRAPHY

US
€4,477 M

EUROPE
€2,483 M



REST OF THE WORLD
€3,472 M

COMMITMENT TO BOLD ACTION AGAINST CLIMATE CHANGE



Carbon neutrality by 2030



Net zero emissions across our operations and value chain by 2050

A 20-year acceleration versus previous targets

For further information on Q3 2021 results and definitions of financial indicators, please refer to the press release issued on October 28, 2021 at:

<https://www.sanofi.com/en/investors>



Sanofi.com



Sanofi.us

